Wednesday, July 1, 2026
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Agenda Topics

• MODULE 1: Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer
• MODULE 2: Optimizing the Use of Maintenance Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer; Future Directions in this Disease Subtype 

Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Review the pathophysiology and prognosis of hormone receptor (HR)-positive, HER2-positive breast cancer, and understand the implications for therapeutic decision-making.
• Appraise available clinical research data, current guideline recommendations and expert best practices to guide the selection of first-line and maintenance therapy for patients with newly diagnosed HR-positive, HER2-positive metastatic breast cancer (mBC). 
• Assess recently published Phase III data with HER2-directed antibody-drug conjugate therapy as a component of first-line therapy, and consider the current role of this novel strategy in treatment for patients with HR-positive, HER2-positive mBC. 
• Appreciate the biological rationale for and available research findings with CDK4/6 inhibition in combination with endocrine and anti-HER2 maintenance therapy for patients with HR-positive, HER2-positive mBC, and use this information to personalize treatment recommendations. 

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology. 

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

Dr Carey has no relevant financial relationships to report.

Dr Mahtani — Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Pfizer Inc, Stemline Therapeutics Inc; Consulting Agreements: Agendia Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Novartis, Pfizer Inc, Puma Biotechnology Inc, Stemline Therapeutics Inc; Contracted Research (Paid to Institution): Gilead Sciences Inc.  

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc. 

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by an educational grant from Pfizer Inc.

Thursday, June 11, 2026
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

MODULE 1: Sequencing of Treatment for CLL

• Impact of the evolving up-front treatment paradigm on the management of relapsed/refractory (R/R) CLL
• Clinical and biological factors guiding decision-making for individual patients with R/R CLL
• Current role of rechallenging with an agent or class of agents administered in a prior line of therapy
• FDA approval of acalabrutinib with venetoclax for previously untreated CLL, based on results of the Phase III AMPLIFY trial

MODULE 2: The Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor Pirtobrutinib

• Mechanistic similarities and differences between noncovalent and covalent BTK inhibitors; implications for efficacy and tolerability
• Extended follow-up from the Phase I/II BRUIN study of pirtobrutinib for patients with R/R CLL
• FDA approval and current role of pirtobrutinib in the treatment of R/R CLL
• Published efficacy and safety findings from the Phase III BRUIN CLL-321 trial evaluating pirtobrutinib versus investigator’s choice of idelalisib/rituximab or bendamustine/rituximab for BTK inhibitor-pretreated CLL
• Tolerability profile of pirtobrutinib as compared to a covalent BTK inhibitor; optimal approaches for managing common toxicities
• Study design and eligibility criteria for the ongoing BRUIN CLL-322 trial evaluating pirtobrutinib, venetoclax and rituximab versus venetoclax and rituximab for previously treated CLL/small lymphocytic lymphoma
• Recently published data from the Phase III BRUIN CLL-314 trial comparing pirtobrutinib to ibrutinib for patients with CLL, including for those with treatment-naïve disease
• Recently published data from the Phase III BRUIN CLL-313 trial comparing pirtobrutinib to bendamustine/rituximab for previously untreated CLL.
• Potential clinical role of pirtobrutinib for newly diagnosed CLL

MODULE 3: Chimeric Antigen Receptor T-Cell Therapy for CLL

• Published efficacy and safety findings with lisocabtagene maraleucel (liso-cel) for R/R CLL from the Phase I/II TRANSCEND CLL 004 trial
• FDA accelerated approval of liso-cel for CLL previously treated with a BTK inhibitor and a Bcl-2 inhibitor; current clinical role and optimal patient selection

MODULE 4: Bispecific Antibodies and Other Promising Investigational Strategies

• Rationale for the investigation of bispecific antibodies for R/R CLL; antitumor activity and safety documented with epcoritamab in the Phase Ib/II EPCORE CLL-1 study
• Mechanistic similarities and differences between BTK degraders and BTK inhibitors
• Preliminary safety and efficacy of the BTK degrader BGB-16673 for patients with heavily pretreated CLL in the Phase I CaDAnCe-101 study
• Other promising agents and strategies under investigation for CLL

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to

• Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection of therapy for patients who experience relapse after first-line treatment for CLL.
• Appraise the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and recognize the implications for clinical activity and tolerability.
• Discuss available and emerging clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors, alone and in combination with other therapies, for relapsed/refractory CLL, and use this information to effectively incorporate these agents into the treatment of disease that has previously been treated with a covalent BTK inhibitor.
• Appreciate recent clinical research with noncovalent BTK inhibitors for patients with treatment-naïve or BTK inhibitor-naïve CLL, and discern the implications of these findings for therapeutic selection and sequencing.
• Evaluate the biological rationale for the investigation of CD19-directed chimeric antigen receptor T-cell therapy for CLL, and identify patients for whom this novel therapeutic strategy would be appropriate.
• Appraise clinical investigator best practices for various relapsed/refractory CLL management situations, and leverage this information to improve shared decision-making with patients.
• Recall available and emerging data with novel agents and combination strategies currently under investigation in CLL, and appropriately refer patients for clinical trial participation.

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology. 

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY
Dr Wierda — Consulting/Advisory Boards, No Compensation: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Intellisphere, Johnson & Johnson, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Juno Therapeutics, a Bristol Myers Squibb Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company; Nonrelevant Financial and Nonfinancial Relationships: National Comprehensive Cancer Network (Chair, CLL), Supported by the NIH/NCI under award number P30 CA016672 and used MD Anderson Cancer Center Support Grant (CCSG) shared resources, Wiley China (consulting/advisory board, no compensation).

CONTRIBUTING CLINICAL INVESTIGATORS
Inhye Ahn, MD — Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeOne, Lilly; Contracted Research: BeOne, Genentech, a member of the Roche Group, Lilly. Catherine C Coombs, MD — Advisory Committees: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Johnson & Johnson, Lilly, Pharmacyclics LLC, an AbbVie Company; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Lilly, Octapharma; Contracted Research: AbbVie Inc, BeOne, Carna Biosciences, Lilly; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, BeOne, Lilly; Stock Options/Stock — Public Companies: Geron Corporation. Matthew S Davids, MD, MMSc — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Galapagos NV, Genentech, a member of the Roche Group, Genmab US Inc, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Nuvalent, Schrödinger, Takeda Pharmaceuticals USA Inc; Contracted Research: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, MEI Pharma Inc, Novartis; Nonrelevant Financial Relationships: UpToDate. Bita Fakhri, MD, MPH — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, BeOne, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company. Nicole Lamanna, MD — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Octapharma, Oncternal Therapeutics. Jennifer Woyach, MD — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Newave, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Karyopharm Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MingSight Pharmaceuticals, MorphoSys, Schrödinger, Verastem Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by an educational grant from Lilly.

STEERING COMMITTEE

Inhye Ahn

MD

Dana-Farber Cancer Institute Boston, Massachusetts

Assistant Professor of Medicine

Farrukh T Awan

MD

University of Texas Southwestern Medical Center, Dallas, Texas

Professor of Internal Medicine, Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapies, Director of Lymphoid Malignancies Program, Harold C Simmons Comprehensive Cancer Center

Catherine C Coombs

MD

UCI Health, Orange County, California

Associate Clinical Professor, Division of Hematology/Oncology, Department of Medicine

Matthew S Davids

MD, MMSc

Harvard Medical School, Boston, Massachusetts

Associate Professor of Medicine

Dana-Farber/Harvard Cancer Center, Boston, Massachusetts

Leader, Lymphoma Program

Dana-Farber Cancer Institute, Boston, Massachusetts

Director of Clinical Research, Division of Lymphoma

Bita Fakhri

MD, MPH

Stanford University School of Medicine, Stanford, California

Associate Professor of Medicine (Hematology)

Nicole Lamanna

MD

NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York

Judy Horrigan Professor of Medicine, Director of the Chronic Lymphocytic Leukemia Program, Leukemia Service, Hematologic Malignancies Section, Herbert Irving Comprehensive Cancer Center

Jeff Sharman

MD

Sarah Cannon Research Institute at Willamette Valley Cancer Center Eugene, Oregon

Medical Director of Hematology Research

Meghan C Thompson

MD

Memorial Sloan Kettering Cancer Center New York, New York

Oncologist and Clinical Investigator Chronic Lymphocytic Leukemia Assistant Attending, Leukemia Service

William G Wierda

MD, PhD

The University of Texas MD Anderson Cancer Center, Houston, Texas

Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr Elihu Estey, Section Chief, Chronic Lymphocytic Leukemia, Center Medical Director, Department of Leukemia, Division of Cancer Medicine, Executive Medical Director, Inpatient Medical Services

Jennifer Woyach

MD

The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Professor, Division of Hematology, Department of Internal Medicine

Each 1-hour session will include 4 topic modules focused on optimizing treatment for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Each event will employ an identical format that will include the following elements:

• Discussion of Steering Committee Members’ Treatment Recommendations
• Review of Available Clinical Research Findings
• Integration of Interactive Audience Q&A Discussion

MODULE 1 | Sequencing of Treatment for CLL

• Impact of the evolving up-front treatment paradigm on the management of relapsed/refractory (R/R) CLL
• Clinical and biological factors guiding decision-making for individual patients with R/R CLL
• Current role of rechallenging with an agent or class of agents administered in a prior line of therapy
• FDA approval of acalabrutinib with venetoclax for previously untreated CLL, based on results of the Phase III AMPLIFY trial

MODULE 2 | The Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor Pirtobrutinib

• Mechanistic similarities and differences between noncovalent and covalent BTK inhibitors; implications for efficacy and tolerability
• Extended follow-up from the Phase I/II BRUIN study of pirtobrutinib for patients with R/R CLL
• FDA approval and current role of pirtobrutinib in the treatment of R/R CLL
• Published efficacy and safety findings from the Phase III BRUIN CLL-321 trial evaluating pirtobrutinib versus investigator’s choice of idelalisib/rituximab or bendamustine/rituximab for BTK inhibitor-pretreated CLL
• Tolerability profile of pirtobrutinib as compared to a covalent BTK inhibitor; optimal approaches for managing common toxicities
• Study design and eligibility criteria for the ongoing BRUIN CLL-322 trial evaluating pirtobrutinib, venetoclax and rituximab versus venetoclax and rituximab for previously treated CLL/small lymphocytic lymphoma
• Recently published data from the Phase III BRUIN CLL-314 trial comparing pirtobrutinib to ibrutinib for patients with CLL, including for those with treatment-naïve disease
• Recently published data from the Phase III BRUIN CLL-313 trial comparing pirtobrutinib to bendamustine/rituximab for previously untreated CLL
• Potential clinical role of pirtobrutinib for newly diagnosed CLL

MODULE 3 | Chimeric Antigen Receptor T-Cell Therapy for CLL

• Published efficacy and safety findings with lisocabtagene maraleucel (liso-cel) for R/R CLL from the Phase I/II TRANSCEND CLL 004 trial
• FDA accelerated approval of liso-cel for CLL previously treated with a BTK inhibitor and a Bcl-2 inhibitor; current clinical role and optimal patient selection

MODULE 4 | Bispecific Antibodies and Other Promising Investigational Strategies

• Rationale for the investigation of bispecific antibodies for R/R CLL; antitumor activity and safety documented with epcoritamab in the Phase Ib/II EPCORE CLL-1 study
• Mechanistic similarities and differences between BTK degraders and BTK inhibitors
• Preliminary safety and efficacy of the BTK degrader BGB-16673 for patients with heavily pretreated CLL in the Phase I CaDAnCe-101 study
• Other promising agents and strategies under investigation for CLL

Each session will conclude with a 5-minute Q&A segment.

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives

• Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection of therapy for patients who experience relapse after first-line treatment for CLL.
• Appraise the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and recognize the implications for clinical activity and tolerability.
• Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for relapsed/refractory CLL, and use this information to effectively incorporate these agents into the treatment of disease that has previously been treated with a covalent BTK inhibitor.
• Appreciate recent clinical research with noncovalent BTK inhibitors for patients with treatment-naïve or BTK inhibitor-naïve CLL, and discern the implications of these findings for therapeutic selection and sequencing.
• Evaluate the biological rationale for the investigation of CD19-directed chimeric antigen receptor T-cell therapy for CLL, and identify patients for whom this novel therapeutic strategy would be appropriate.
• Appraise clinical investigator best practices for various relapsed/refractory CLL management situations, and leverage this information to improve shared decision-making with patients.
• Recall available and emerging data with novel agents and combination strategies currently under investigation in CLL, and appropriately refer patients for clinical trial participation.

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology. 

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
These educational activities may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantor.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

Steering Committee
Dr Ahn — Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeOne, Lilly; Contracted Research: BeOne, Genentech, a member of the Roche Group, Lilly. Dr Awan — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, DAVA Oncology, Genmab US Inc, Incyte Corporation, Invivyd, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, Pierre Fabre; Contracted Research: Actinium Pharmaceuticals Inc, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Boards/Committees: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Caribou Biosciences Inc. Dr Coombs — Advisory Committees: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Johnson & Johnson, Lilly, Pharmacyclics LLC, an AbbVie Company; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Lilly, Octapharma; Contracted Research: AbbVie Inc, BeOne, Carna Biosciences, Lilly; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, BeOne, Lilly; Stock Options/Stock — Public Companies: Geron Corporation. Dr Davids — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Galapagos NV, Genentech, a member of the Roche Group, Genmab US Inc, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Nuvalent, Schrödinger, Takeda Pharmaceuticals USA Inc; Contracted Research: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, MEI Pharma Inc, Novartis; Nonrelevant Financial Relationships: UpToDate. Dr Fakhri — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, BeOne, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company. Dr Lamanna — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Octapharma, Oncternal Therapeutics. Dr Sharman — Advisory Committees: AbbVie Inc, Genentech, a member of the Roche Group, Novartis; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Lilly. Dr Thompson — Advisory Boards and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc; Research Funding (Paid to Institution): AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc; Travel Support: DAVA Oncology. Dr Wierda — Consulting/Advisory Boards, No Compensation: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Intellisphere, Johnson & Johnson, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Juno Therapeutics, a Bristol Myers Squibb Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company; Nonrelevant Financial and Nonfinancial Relationships: National Comprehensive Cancer Network (Chair, CLL), Supported by the NIH/NCI under award number P30 CA016672 and used MD Anderson Cancer Center Support Grant (CCSG) shared resources, Wiley China (consulting/advisory board, no compensation). Dr Woyach — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Newave, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Karyopharm Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MingSight Pharmaceuticals, MorphoSys, Schrödinger, Verastem Inc.

Program Chair
Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporter
These activities are supported by an educational grant from Lilly.

Thursday, June 25, 2026
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Module 1: Current and Emerging Therapeutic Approaches for Multiple Myeloma  
• Module 2: Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates 

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appreciate available clinical trial findings evaluating anti-CD38 monoclonal antibody therapy for patients with high-risk smoldering multiple myeloma (MM), and consider the role of this novel treatment strategy. 
• Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for patients with MM eligible and ineligible for stem cell transplant, and use this information to optimize therapeutic recommendations.  
• Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory (R/R) MM.  
• Evaluate published research findings to identify patients with R/R MM for whom treatment with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) should be considered or recommended. 
• Assess available research data with BCMA- and non-BCMA-directed bispecific antibodies for MM to appropriately integrate these agents into current clinical algorithms.  
• Recall recently presented clinical research findings establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for patients with R/R MM.  
• Analyze the mechanism of action of, published and emerging efficacy and safety findings with and ongoing research efforts evaluating cereblon E3 ligase modulators to prepare for the potential clinical availability of these agents for patients with R/R MM.  
• Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly employed for MM. 

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology. 

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Krishnan — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer Inc, Roche Laboratories Inc, Sanofi; Stock Options/Stock — Public Companies: Bristol Myers Squibb. Dr Orlowski — Advisory Committees and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, Biotheryx, Bristol Myers Squibb, DEM BioPharma, GSK, IASO Bio, Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, MYELOMA360, Neurogene Inc, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Sporos Bioventures, Takeda Pharmaceuticals USA Inc; Contracted Research: Asylia Therapeutics Inc, Biotheryx, Heidelberg Pharma, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: Sanofi. Dr Orlowski — Advisory Committees and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, Biotheryx, Bristol Myers Squibb, DEM BioPharma, GSK, IASO Bio, Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, MYELOMA360, Neurogene Inc, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Sporos Bioventures, Takeda Pharmaceuticals USA Inc; Contracted Research: Asylia Therapeutics Inc, Biotheryx, Heidelberg Pharma, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: Sanofi.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc. 

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals Inc.

Faculty

Faculty

Claire Harrison

Professor

Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Professor of Myeloproliferative Neoplasms

Faculty

Raajit K Rampal

MD, PhD

Memorial Sloan Kettering Cancer Center, New York, New York

Associate Member, Director, MPN and Rare Hematologic Malignancies Program, Director, Center for Hematologic Malignancies

Moderator

Neil Love

MD

Research To Practice

Miami, Florida

Topics to Be Discussed 

• Biology of Myelofibrosis (MF); Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias 
• Managing MF for Patients with Anemia and Thrombocytopenia

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals involved in the treatment of myelofibrosis.

Learning Objectives
Upon completion of this activity, participants should be able to

• Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with myelofibrosis (MF) regarding their long-term prognosis.  
• Analyze how age, performance status and other biological and disease-related factors affect the selection and sequencing of therapy for patients with primary and secondary MF. 
• Appraise available research findings informing the safety and efficacy of approved JAK inhibitors for patients with MF. 
• Evaluate published research findings with JAK inhibitors for patients with MF and anemia to optimize decision-making for this population. 
• Review available research data with and the current clinical role of novel JAK inhibitors for patients with MF and severe thrombocytopenia. 
• Understand the biological rationale for the inhibition of exportin 1 (XPO1) for patients with MF, and reflect on available and emerging research findings with XPO1 inhibitors in combination with JAK inhibitors as front-line treatment. 
• Recall available research findings with combination regimens incorporating JAK inhibitors and other novel investigational agents, and consider the role of these emerging approaches in treatment.

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Harrison — Advisory Committees: Alethiomics, AOP Health, Calytrix Bio, Galecto Inc, GSK, Incyte Corporation, Janssen Biotech Inc, Kartos Therapeutics, Karyopharm Therapeutics, Menarini Group, Novartis, Stemline Therapeutics Inc, Takeda Pharmaceutical Company Limited; Consulting Agreements: Alethiomics, AOP Health, Calytrix Bio, Galecto Inc, GSK, Incyte Corporation, Janssen Biotech Inc, Kartos Therapeutics, Karyopharm Therapeutics, Menarini Group, MSD, Novartis, Stemline Therapeutics Inc, Takeda Pharmaceutical Company Limited; Contracted Research: GSK, Novartis; Data and Safety Monitoring Boards/Committees: Deciphera Pharmaceuticals Inc, Silence Therapeutics, Takeda Pharmaceutical Company Limited; Speakers Bureaus: GSK, Menarini Group, MSD, Novartis, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: Owner private LLP, trustee MPN Voice and Blood Cancer UK. Dr Rampal — Consulting Agreements: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Galecto Inc, GSK, Incyte Corporation, Jazz Pharmaceuticals Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, Opna Bio, PharmaEssentia, Roche Laboratories Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Zentalis Pharmaceuticals; Contracted Research: BioMed Valley Discoveries, Incyte Corporation, MorphoSys, Ryvu Therapeutics, Stemline Therapeutics Inc, Zentalis Pharmaceuticals; Data and Safety Monitoring Boards/Committees: Merck.

CONTRIBUTING CLINICAL INVESTIGATORS
Prithviraj Bose, MD — Advisory Committees: Blueprint Medicines, Geron Corporation, GSK, Karyopharm Therapeutics, Keros Therapeutics, PharmaEssentia, Sumitomo Dainippon Pharma Oncology Inc; Consulting Agreements: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Geron Corporation, GSK, Incyte Corporation, Ionis Pharmaceuticals Inc, Jubilant Pharma Limited, Karyopharm Therapeutics, Keros Therapeutics, Morphic Therapeutic, a wholly owned subsidiary of Lilly, MorphoSys, Novartis, Ono Pharmaceutical Co Ltd, PharmaEssentia, RayThera, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: Ajax Therapeutics, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, GSK, Incyte Corporation, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Sumitomo Dainippon Pharma Oncology Inc, Telios Pharma Inc. Andrew T Kuykendall, MD — Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Incyte Corporation, Karyopharm Therapeutics, PharmaEssentia; Consulting Agreements: AbbVie Inc, Karyopharm Therapeutics, MorphoSys; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Geron Corporation, Janssen Biotech Inc, MorphoSys, Protagonist Therapeutics; Data and Safety Monitoring Boards/Committees: Geron Corporation. John Mascarenhas, MD — Consulting Agreements: Bristol Myers Squibb, Disc Medicine, Geron Corporation, GSK, Incyte Corporation, Italfarmaco SpA, Kartos Therapeutics, Karyopharm Therapeutics, Keros Therapeutics, Merck, MorphoSys, Novartis, PharmaEssentia, Roche Laboratories Inc, Sobi, Sumitomo Pharma America; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Disc Medicine, Incyte Corporation, Italfarmaco SpA, Kartos Therapeutics, Karyopharm Therapeutics, Novartis, PharmaEssentia, Sobi; Data and Safety Monitoring Boards/Committees: Incyte Corporation. Abdulraheem Yacoub, MD — Consulting Agreements: Blueprint Medicines, GSK, Incyte Corporation, Karyopharm Therapeutics, Novartis, PharmaEssentia, Protagonist Therapeutics, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Contracted Research: CTI BioPharma, a Sobi Company, Stemline Therapeutics Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from GSK and Karyopharm Therapeutics.

Faculty

Faculty

Manish A Shah

MD

Weill Cornell Medicine NewYork-Presbyterian Hospital, New York, New York

Professor of Medicine, Bartlett Family Professor of Gastrointestinal Oncology, Chief, Solid Tumor Oncology

Faculty

Eric Van Cutsem

MD, PhD

University Hospitals Leuven, Leuven, Belgium

Professor of Medicine, Digestive Oncology

Moderator

Yelena Y Janjigian

MD

Memorial Sloan Kettering Cancer Center, New York, New York

Carroll and Milton Petrie Chair, Professor and Chief Attending, Gastrointestinal Oncology Service

Program Schedule — Central Time
11:15 AM – 11:30 AM — Registration
11:30 AM – 1:00 PM — Educational Lunch Meeting

MODULE 1: Targeting CLDN18.2 in Advanced Gastroesophageal Cancers

• Incidence and clinical relevance of CLDN18.2 expression in gastric and gastroesophageal junction (GEJ) cancer; appropriate methods to assess CLDN18.2 status
• Key efficacy and safety results from the Phase III SPOTLIGHT and GLOW trials evaluating zolbetuximab in combination with chemotherapy as first-line treatment for CLDN18.2-positive advanced gastric/GEJ adenocarcinoma
• FDA approval and current clinical role of up-front zolbetuximab/chemotherapy
• Spectrum, frequency and severity of adverse events associated with zolbetuximab; optimal approaches to prevention and management
• Recently presented results with zolbetuximab in combination with modified FOLFOX6 and nivolumab for patients with CLDN18.2-positive advanced gastric or GEJ adenocarcinoma in the Phase II ILUSTRO trial; implications for current and future practice
• Design, eligibility criteria and key efficacy and safety endpoints of the Phase III LUCERNA trial evaluating zolbetuximab in combination with pembrolizumab and chemotherapy as first-line treatment for CLDN18.2-positive, HER2-negative, PD-L1-positive gastric/GEJ cancer
• Structural components of the CLDN18.2-targeted antibody-drug conjugate sonesitatug vedotin and early efficacy and safety results with this therapy for advanced gastroesophageal cancers

MODULE 2: HER2-Targeted Approaches for Advanced Gastroesophageal Cancers

• Available efficacy and safety findings with and current clinical role of trastuzumab/pembrolizumab/chemotherapy for patients with untreated HER2-positive advanced gastric/GEJ adenocarcinoma
• Mechanism of action of the novel HER2-targeted bispecific antibody zanidatamab
• Design, eligibility criteria and key efficacy and safety endpoints of the Phase III HERIZON-GEA-01 trial evaluating zanidatamab/chemotherapy with or without tislelizumab as first-line treatment for gastroesophageal adenocarcinoma
• Recently presented results from the HERIZON-GEA-01 trial demonstrating a progression-free survival (PFS) and overall survival advantage with zanidatamab/chemotherapy/tislelizumab and a PFS benefit with zanidatamab/chemotherapy; implications for future disease management
• Spectrum, frequency and optimal approaches to the management of toxicities associated with zanidatamab
• Published efficacy and safety data from the Phase III DESTINY-Gastric04 trial comparing trastuzumab deruxtecan (T-DXd) to ramucirumab/paclitaxel for patients with HER2-positive metastatic gastric cancer or GEJ adenocarcinoma who had previously received trastuzumab-based therapy
• Optimal integration of T-DXd into the current management of advanced HER2-positive gastroesophageal tumors

MODULE 3: Available Immunotherapeutic Strategies for Advanced Gastroesophageal Cancers

• Clinical and biological factors in the choice of up-front therapy for patients with metastatic gastroesophageal cancers
• Published datasets demonstrating the efficacy and safety of first-line nivolumab-, pembrolizumab- and tislelizumab-containing regimens for advanced HER2-negative gastric, GEJ and esophageal cancers; impact of PD-L1 expression on outcomes
• Recent narrowing of the FDA-approved indications for nivolumab- and pembrolizumab-containing regimens for previously untreated HER2-negative gastroesophageal cancers
• Clinical utility, if any, of immunotherapy for relapsed/refractory gastroesophageal tumors
• Optimal approaches to the prevention and management of toxicities observed with immune checkpoint inhibitors

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastroesophageal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

• Assess available data with monoclonal antibody therapy directed at claudin 18.2 (CLDN18.2) in combination with chemotherapy as first-line treatment for patients with HER2-negative, CLDN18.2-positive gastric or gastroesophageal junction (GEJ) cancer, and optimally incorporate this approach into management algorithms.
• Review published research findings with HER2-targeted therapies for patients with HER2-positive gastroesophageal cancers, and assess the current nonresearch role of various agents and regimens.
• Describe the published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies in the management of metastatic gastric, GEJ and esophageal cancer, and optimally integrate these strategies into treatment algorithms.
• Recognize the spectrum, frequency and severity of toxicities associated with agents and regimens with established activity in advanced gastroesophageal cancers in order to facilitate the safe and effective use of these therapies.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Shah has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Prof Van Cutsem — Consulting Agreements: AbbVie Inc, Agenus Inc, ALX Oncology, Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeOne, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Cantargia, Daiichi Sankyo Inc, Debiopharm, Eisai Inc, ElmediX, Fosun Pharma, Galapagos NV, GSK, Incyte Corporation, Ipsen Biopharmaceuticals Inc, iTeos Therapeutics, Jazz Pharmaceuticals Inc, Johnson & Johnson, Lilly, Merck KGaA, Microbial Machines, Mirati Therapeutics Inc, MSD, Nordic Pharma, Novartis, Novocure Inc, Pfizer Inc, Pierre Fabre, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Simcere, Taiho Oncology Inc, Takeda Pharmaceutical Company Limited, Trishula Therapeutics, Zymeworks Inc. 

CONTRIBUTING CLINICAL INVESTIGATORS
Sunnie Kim, MD — Advisory Committees: AstraZeneca Pharmaceuticals LP, BeOne, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Amgen Inc; Contracted Research: Merck; Data and Safety Monitoring Boards/Committees: Jazz Pharmaceuticals Inc. Samuel J Klempner, MD — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, BeOne, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, EsoBiotec, Gilead Sciences Inc, I-Mab Biopharma, Jazz Pharmaceuticals Inc, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Signet Therapeutics, Taiho Oncology Inc; Consulting Agreements: Astellas; Contracted Research: Arcus Biosciences, AstraZeneca Pharmaceuticals LP, I-Mab Biopharma, Mersana Therapeutics Inc, Parabilis Medicines; Data and Safety Monitoring Boards/Committees: Sanofi; Stock OPTIONS — Private Companies: MBrace Therapeutics; Nonrelevant Financial Relationships: Debbie’s Dream Foundation, Degregorio Family Foundation, Gastric Cancer Foundation, National Cancer Institute/National Institutes of Health, NCCN (member of Gastric and Esophageal Guidelines Committees), Stand Up 2 Cancer/AACR, Torrey Coast Foundation. Zev Wainberg, MD, MSc — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, EMD Serono Inc, Gilead Sciences Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Novartis, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Arcus Biosciences, Bristol Myers Squibb; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, Pfizer Inc.

MODERATOR
Dr Janjigian — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc; Consulting Agreements: AbbVie Inc, AlphaSights, Arcus Biosciences, ARS Pharmaceuticals, AskGene Pharma, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, BeOne, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Cencora, Daiichi Sankyo Inc, Eisai Inc, Geneos Therapeutics, Gilead Sciences Inc, GSK, Guardant Health, HC Wainwright & Co, Health Advances, Imugene, Inspirna, Lilly, Lynx Health, Merck, Merck Serono, Mersana Therapeutics Inc, PeerMD, Pfizer Inc, Sanofi, Seagen Inc, Suzhou Liangyihui Network Technology Co Ltd, Zymeworks Inc; Contracted Research: Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Genentech, a member of the Roche Group, Inspirna, Lilly, Merck, Transcenta; Nonrelevant Financial Relationships: Clinical Care Options, Cycle for Survival, Debbie’s Dream Foundation, eChinaHealth, ED Medresources Inc, Fred’s Team, HMP, i3Health, Imedex, Mashup Media LLC, Master Clinician Alliance, MJH Life Sciences, National Cancer Institute, OncoDaily (stock options), Paradigm Medical Communications, PeerView, Physician Education Resource (PER), Stand Up 2 Cancer, Talem Health, TotalCME, US Department of Defense, WebMD.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Astellas and Jazz Pharmaceuticals Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room A (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 11:00 AM on Friday, May 29th. If you are interested in attending, please visit the registration desk outside Continental Room A (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).

Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

Tuesday, June 23, 2026
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers
• Other Available Therapeutic Approaches for Patients with Gastroesophageal Cancers

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastroesophageal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate recently presented clinical research findings to determine their effect on the current management of gastric, gastroesophageal junction (GEJ) and esophageal cancers.
• Recognize available clinical research findings with immune checkpoint inhibitors as neoadjuvant, adjuvant or perioperative therapy for patients with resectable gastric, GEJ and esophageal cancers, and consider the current role of these approaches.
• Describe published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies in the management of metastatic gastric, GEJ and esophageal cancers, and optimally integrate these strategies into treatment algorithms.
• Assess available data with monoclonal antibody therapy directed at claudin 18.2 (CLDN18.2) in combination with chemotherapy as first-line treatment for patients with HER2-negative, CLDN18.2-positive gastric or GEJ cancer, and optimally incorporate this approach into management algorithms.
• Review published research findings with established HER2-targeted therapies for patients with HER2-positive gastroesophageal cancers, and assess the current role of various agents and regimens.
• Review the rationale for, available data with and ongoing research studies evaluating novel agents and strategies for patients with gastroesophageal cancers in preparation for potential clinical availability or to enhance trial participation.

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology. 

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — Dr Shitara has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Ilson — Advisory Committees: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Lilly, Merck, Oncolys BioPharma, Roche Laboratories Inc, Taiho Oncology Inc; Consulting Agreements: Astellas.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeOne, and Daiichi Sankyo Inc.

Tuesday, June 30, 2026
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Therapeutic Approaches Targeting HER2, MET and KRAS G12C
• Therapeutic Approaches Targeting ALK, ROS1, RET and TRK

Target Audience
This activity is intended for medical oncologists, radiation oncologists, surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Consider emerging research information and available guideline recommendations to individualize first- and later-line therapy for patients with non-small cell lung cancer (NSCLC) harboring various targetable genetic abnormalities beyond EGFR.
• Appreciate the incidence of c-Met overexpression in metastatic NSCLC, and recognize published clinical trial data with and the current role of novel antibody-drug conjugates in treatment for patients with high levels of this newly relevant biomarker.
• Review available clinical trial data evaluating the efficacy and safety of HER2-targeted tyrosine kinase inhibitors for patients with HER2-mutant NSCLC, and optimally identify individuals for whom treatment with this novel therapeutic strategy would be appropriate.
• Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate candidates with localized and metastatic NSCLC.
• Convey the clinical relevance of a positive ROS1 mutation testing result to patients with NSCLC as appropriate, and appreciate available research findings with approved and emerging agents demonstrating efficacy in this disease.
• Assess available research evidence with approved RET inhibitors, and use this information to appropriately guide clinical care for patients with newly diagnosed or progressive NSCLC.
• Understand the biology of KRAS G12C mutations, and evaluate available research findings with approved and investigational agents with documented activity in patients with these abnormalities.
• Recollect other oncogenic drivers (eg, BRAF V600E, MET exon 14, NRG1, NTRK) mediating the pathogenesis of NSCLC in unique patient subsets, and recall published data with commercially available and experimental agents exploiting these targets.

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology. 

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Heymach — Advisory Committees and Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, GSK, Jazz Pharmaceuticals Inc, Johnson & Johnson, Lilly, Mirati Therapeutics Inc, ModeX Therapeutics, OncoHost, Ottimo Pharma, Pfizer Inc, Regeneron Pharmaceuticals Inc, Remunity Therapeutics, Spectrum Pharmaceuticals Inc, Synthekine, Takeda Pharmaceuticals USA Inc; Royalties and Licensing Fees: Spectrum Pharmaceuticals Inc. Prof Pérol — Advisory Committees: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, MSD, Novocure Inc, Nuvation Bio Inc, Pfizer Inc, PharmaMar, Sanofi, Takeda Pharmaceutical Company Limited; Consulting Agreements: Bristol Myers Squibb, Daiichi Sankyo Inc, MSD, Pfizer Inc; Data and Safety Monitoring Boards/Committees: PharmaMar; Speakers Bureaus: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Chugai Pharmaceutical Co Ltd, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, MSD, Novocure Inc, Pfizer Inc, Sanofi, Takeda Pharmaceutical Company Limited.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, and Nuvation Bio Inc.

Faculty

Faculty

Christopher Flowers

MD, MS, FASCO

The University of Texas MD Anderson Cancer Center, Houston, Texas

Division Head, Division of Cancer Medicine, Chair, Professor, Department of Lymphoma/Myeloma, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine

Faculty

Matthew Lunning

DO

University of Nebraska Medical Center, Omaha, Nebraska

Professor, Chief of Hematology, Interim, Medical Director, Gene and Cellular Therapy, Assistant Vice Chancellor for Clinical Research, Fred and Pamela Buffett Cancer Center

Faculty

Sonali M Smith

MD

The University of Chicago, Chicago, Illinois

Elwood V Jensen Professor of Medicine, Chief, Section of Hematology/Oncology, Co-Leader, Cancer Service Line

Moderator

Brad S Kahl

MD

Washington University School of Medicine, St Louis, Missouri

Professor of Medicine

Siteman Cancer Center, St Louis, Missouri

Director, Lymphoma Program

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

• Key factors in the selection of initial therapy for patients with DLBCL
• Extended follow-up from the Phase III POLARIX trial comparing polatuzumab vedotin with rituximab/cyclophosphamide/doxorubicin/prednisone (R-CHP) to R-CHOP for patients with previously untreated DLBCL; clinical activity observed with polatuzumab vedotin/R-CHP in various patient subsets
• Appropriate selection of patients to receive polatuzumab vedotin as a component of up-front therapy for DLBCL
• Efficacy and safety findings from the Phase III POLARGO study of polatuzumab vedotin in combination with rituximab, gemcitabine and oxaliplatin for patients with R/R DLBCL; potential role of this regimen
• Available results, including those from the Phase III SUNMO trial, with polatuzumab vedotin combined with bispecific antibodies for patients with R/R DLBCL

MODULE 2: Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL)

• Extended follow-up from the Phase II L-MIND study supporting the use of tafasitamab/lenalidomide for patients with R/R DLBCL; optimal sequencing for individual patients
• Emerging positive findings from the Phase III frontMIND trial assessing tafasitamab and lenalidomide with R-CHOP versus R-CHOP alone as first-line therapy for DLBCL 
• Biological rationale for the evaluation of tafasitamab for FL
• Key efficacy and safety findings from the Phase III inMIND trial evaluating the addition of tafasitamab to lenalidomide and rituximab (R2) for R/R FL or marginal zone lymphoma
• FDA approval of tafasitamab/R2 for patients with R/R FL; selection of appropriate candidates for this approach

MODULE 3: Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL

• Extended follow-up from the Phase II LOTIS-2 study supporting the use of loncastuximab tesirine for patients with R/R DLBCL
• Optimal sequencing of loncastuximab tesirine for individual patients with R/R DLBCL and ongoing studies designed to further define its role
• Initial results from the Phase Ib LOTIS-7 study of loncastuximab tesirine in combination with glofitamab for R/R DLBCL; implications for clinical practice and ongoing research
• Available data with loncastuximab tesirine for other subtypes of non-Hodgkin lymphoma (NHL)
• Recent NCCN Guidelines inclusion of loncastuximab tesirine/rituximab as a third- or later-line treatment option for FL; optimal incorporation into practice

MODULE 4: Current and Future Role of Bruton Tyrosine Kinase (BTK) Inhibition in Therapy for Non-Hodgkin Lymphoma

• Key efficacy and safety outcomes with the addition of acalabrutinib to bendamustine/rituximab (BR) and maintenance rituximab for patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for transplant
• Recent FDA approval of acalabrutinib/BR as a front-line regimen for MCL; identification of optimal candidates for this strategy
• Published research findings with and ongoing studies of covalent BTK inhibitors as a component of up-front chemotherapy-free combination regimens for MCL
• Published efficacy and safety data from the Phase II ROSEWOOD study of zanubrutinib in combination with obinutuzumab for patients with FL who had received 2 or more previous systemic therapies; current clinical role
• Published clinical trial experience with BTK inhibitors for patients with newly diagnosed DLBCL
• Design, eligibility criteria and primary and secondary endpoints of the Phase III ESCALADE trial of acalabrutinib in combination with R-CHOP for patients aged 65 or younger with untreated non-GCB DLBCL; estimated completion date

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Identify patients with newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) for whom the use of CD79b-targeted therapy would be appropriate.
• Develop an understanding of published clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents for DLBCL and follicular lymphoma (FL), and apply this information in patient education discussions.
• Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted antibody-drug conjugates for patients with relapsed/refractory (R/R) DLBCL and FL.
• Evaluate available clinical trial findings with Bruton tyrosine kinase inhibitors for patients with mantle cell lymphoma (MCL), FL and DLBCL, and determine the role of these agents in current and future clinical management.
• Assess emerging research findings with Bcl-2 inhibitors for patients with R/R MCL in order to prepare for the potential clinical availability of this novel treatment strategy.
• Recall new data with agents and strategies currently under investigation for various non-Hodgkin lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Flowers — Consulting Agreements: BeOne, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Genentech, a member of the Roche Group, Genmab US Inc, N-Power Medicine; Contracted Research: 4D Pharma PLC, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Alaunos Therapeutics, Allogene Therapeutics, Amgen Inc, BostonGene, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Guardant Health, Iovance Biotherapeutics, Kite, A Gilead Company, MorphoSys, Nektar Therapeutics, Novartis, Pfizer Inc, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor; Stock Options/Stock — Public Companies: Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, N-Power Medicine; Nonrelevant Financial Relationships: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, National Cancer Institute, The V Foundation for Cancer Research. Dr Lunning — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Kite, A Gilead Company, Lyell Immunopharma, Pfizer Inc, Recordati. Dr Smith — Consulting Agreements: Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Genmab US Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Celgene Corporation, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc.

MODERATOR
Dr Kahl — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Incyte Corporation, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc; Contracted Research: BeOne, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: BeOne, Bristol Myers Squibb, Roche Laboratories Inc. 

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, and Incyte Corporation.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room C (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Faculty

Faculty

Melissa Alsina

MD

Moffitt Cancer Center, Tampa, Florida

Head, Myeloma Section, Bone Marrow Transplant and Cellular Immunotherapy Program

Faculty

Hans Lee

MD

Sarah Cannon Research Institute, Nashville, Tennessee

Director, Multiple Myeloma Research

Faculty

Paul G Richardson

MD

Dana-Farber Cancer Institute, Boston, Massachusetts

Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center

Harvard Medical School, Boston, Massachusetts

RJ Corman Professor of Medicine

Moderator

Sagar Lonial

MD, FACP, FASCO

Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia

Chair and Professor, Department of Hematology and Medical Oncology, Chief Medical Officer

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

• Research database documenting the effectiveness of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for patients with heavily pretreated MM
• Published data from the Phase III KarMMa-3 and CARTITUDE-4 trials of ide-cel and cilta-cel, respectively, in earlier lines of treatment; overall survival findings from CARTITUDE-4
• FDA approvals of ide-cel and cilta-cel in earlier settings; identification of patients appropriate for CAR T-cell therapy and optimal sequencing with regard to other evidence-based approaches
• Spectrum, incidence and severity of acute and long-term toxicities with BCMA-directed CAR T-cell therapy in patients with MM; appropriate monitoring and management algorithms
• Rationale for the evaluation of CAR T-cell platforms with novel targets and/or manufacturing processes for R/R MM
• Early data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel for R/R MM; FDA regenerative medicine advanced therapy designation and ongoing evaluation
• Preliminary data and ongoing clinical research with other novel CAR T-cell platforms for R/R MM

MODULE 2: Integrating Bispecific Antibodies into the Management of R/R MM

• Similarities and differences in the cellular targets and mechanisms of action of the various bispecific antibodies used for MM
• Efficacy and safety findings leading to the FDA approvals of the BCMA-directed bispecific antibodies teclistamab, elranatamab and linvoseltamab as monotherapy for heavily pretreated MM
• Published findings from the Phase III MajesTEC-3 trial evaluating the combination of teclistamab and subcutaneous daratumumab for patients with R/R MM after ≥1 prior line of treatment 
• Emerging positive findings from the Phase III MajesTEC-9 and MagnetisMM-5 studies evaluating teclistamab and elranatamab, respectively, as monotherapy in earlier lines of treatment 
• Key efficacy and safety data with the GPRC5D-targeted bispecific antibody talquetamab for heavily pretreated disease
• Selection of appropriate candidates with R/R MM to receive BCMA-directed bispecific antibody monotherapy, talquetamab monotherapy and teclistamab/daratumumab; optimal incorporation regarding other available treatment options 
• Biological rationale for and published findings with the FcRH5-directed bispecific antibody cevostamab in the treatment of R/R MM
• Incidence and severity of cytokine release syndrome, neurotoxicity and other adverse events (AEs) with BCMA- and non-BCMA-targeted bispecific antibodies; optimal mitigation and management strategies

MODULE 3: Current Utility of Antibody-Drug Conjugates for MM

• Mechanism of action and structural components of belantamab mafodotin
• Historical efficacy and safety findings with belantamab mafodotin monotherapy for patients with R/R MM
• Key efficacy and safety data from the Phase III DREAMM-7 and DREAMM-8 trials evaluating belantamab mafodotin in combination with bortezomib/dexamethasone and with pomalidomide/dexamethasone, respectively, for patients who have received ≥1 prior line of therapy; overall survival findings from DREAMM-7
• FDA approval and current role of belantamab mafodotin/bortezomib/dexamethasone in the management of R/R MM
• Incidence, severity, mitigation and management of belantamab mafodotin-related AEs, including ocular toxicities

MODULE 4: Potential Role of Cereblon E3 Ligase Modulators (CELMoDs) in Therapy for MM

• Mechanism of action of CELMoDs; similarities and differences among iberdomide, mezigdomide and standard immunomodulatory drugs (IMiDs)
• Available data documenting the efficacy and safety of iberdomide and mezigdomide as monotherapy and combined with other systemic therapies for patients with R/R MM
• Emerging findings from the Phase III EXCALIBER-RRMM study indicating an improvement in minimal residual disease negativity rates with iberdomide/daratumumab/dexamethasone compared to daratumumab/bortezomib/dexamethasone for patients with R/R MM
• Emerging positive findings from the Phase III SUCCESSOR-2 trial evaluating mezigdomide/carfilzomib/dexa­methasone for R/R MM
• Other ongoing studies evaluating CELMoD-containing therapy for newly diagnosed and R/R MM; potential clinical role of CELMoDs
• Spectrum, frequency and severity of AEs observed with CELMoDs in published clinical studies; comparative tolerability profiles of iberdomide, mezigdomide and traditional IMiDs

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens for patients with relapsed/refractory (R/R) multiple myeloma (MM).
• Evaluate published research findings to identify patients with R/R MM for whom treatment with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) should be considered and/or recommended.
• Assess available research data with BCMA- and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into clinical algorithms.
• Recall presented clinical research establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for patients with R/R MM.
• Analyze the mechanism of action of, published and emerging efficacy and safety findings with and ongoing research evaluating cereblon E3 ligase modulators to prepare for the potential clinical availability of these agents for patients with R/R MM.
• Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly used in the care of patients with R/R MM.
• Recall available data with novel agents and strategies currently under investigation for R/R MM, and as applicable, discuss clinical trial participation with eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Alsina — Advisory Committees: Bristol Myers Squibb, Janssen Biotech Inc, Kite, A Gilead Company, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Janssen Biotech Inc, Pfizer Inc; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb. Dr Lee — Consulting Agreements (Paid to Institution): AbbVie Inc, Alexion Pharmaceuticals, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Legend Biotech, Medline, Pfizer Inc, Predicta Biosciences, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Consulting Agreements (Paid to Self): Alexion Pharmaceuticals, Allogene Therapeutics, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Moderna, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Allogene Therapeutics, Takeda Pharmaceuticals USA Inc. Dr Richardson — Consulting Agreements: Bristol Myers Squibb, Celgene Corporation, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Oncopeptides.

MODERATOR
Dr Lonial — Advisory Committees and Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Boards of Directors: TG Therapeutics Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc; Stock Options/Stock — Public Companies: TG Therapeutics Inc. 

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and GSK.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room B (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 6:30 PM on Monday, June 1st. If you are interested in attending, please visit the registration desk outside Continental Room B (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).

Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.